Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13088144 | 1.00 | HSD11B1 (0.48) | HSD11B1SIGMAR1PHGDHMGLLKMT2A | |
| SCHEMBL7907323 | 0.98 | KMT2A (0.46) | HSD11B1SIGMAR1PHGDHMGLLKMT2A | |
| SCHEMBL23732169 | 0.93 | KMT2A (0.46) | HSD11B1SIGMAR1PHGDHMGLLKMT2A | |
| SCHEMBL14947708 | 0.91 | KMT2A (0.42) | HSD11B1SIGMAR1PHGDHMGLLKMT2A | |
| SCHEMBL7907325 | 0.88 | KMT2A (0.49) | HSD11B1KMT2ATLR7ALOX15 | |
| SCHEMBL11919045 | 0.86 | KMT2A (0.56) | HSD11B1KMT2A | |
| SCHEMBL22814980 | 0.85 | KMT2A (0.41) | HSD11B1SIGMAR1PHGDHMGLLKMT2A | |
| SCHEMBL18874058 | 0.84 | KMT2A (0.44) | HSD11B1SIGMAR1KMT2ATLR7HTR7 | |
| SCHEMBL17722606 | 0.84 | SIGMAR1 (0.53) | HSD11B1SIGMAR1PHGDHMGLLHTR7 | |
| SCHEMBL17722612 | 0.84 | SIGMAR1 (0.53) | HSD11B1SIGMAR1PHGDHMGLLHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-3828174-A1 | PYRIDAZINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-10208000-B2 | Eis inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-9724435-B2 | Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders | THE UNIVERSITY OF MISSISSIPPI (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2841414-B1 | METHOD FOR ISOMERISATION OF CIS-2-PENTENNITRIL TO 3-PENTENNITRIL | BASF SE (DE) | 2016-06-08 | — | — | EP | disclosed |
| US-8772527-B2 | Process for isomerization of cis-2-pentenenitrile to 3-pentenenitriles | BASF SE (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130289299-A1 | Process for Isomerization of CIS-2-Pentenenitrile to 3-Pentenenitriles | BASF SE (DE) | 2013-10-31 | — | — | US | disclosed |
| EP-2657224-A1 | Method for isomerisation of cis-2-Pentennitril to 3-Pentennitril | BASF SE (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2009021944-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025673-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008127722-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY USING TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008106619-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174639-A1 | EIS INHIBITORS | ABCC1, ATP5ME, ABCG2 | HSD11B1 2713/4885SIGMAR1 3243/4885PHGDH 376/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | HSD11B1 2348/4885SIGMAR1 1308/4885PHGDH 813/4885 |
| US-20130289299-A1 | Process for Isomerization of CIS-2-Pentenenitrile to 3-Pentenenitriles | PORCN, PIN1, ORAI2 | HSD11B1 391/4885SIGMAR1 2924/4885PHGDH 1805/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | HSD11B1 1397/4885SIGMAR1 3790/4885PHGDH 1199/4885 |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, NCOA4 | HSD11B1 171/4885SIGMAR1 4134/4885PHGDH 2545/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | HSD11B1 1397/4885SIGMAR1 3790/4885PHGDH 1199/4885 |
| US-10208000-B2 | Eis inhibitors | ABCC1, ATP5ME, ABCG2 | HSD11B1 2713/4885SIGMAR1 3243/4885PHGDH 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.